Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A1250 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.


Download subscription form here



Latest News !

Neuren, Acadia $630m North America Trofinetide Licence

Dr Boreham's Crucible: Elixinol Global

Benitec Up 124% On Up-To $892m Axovant Gene Therapy Deal

Prana Back In The Clinic With PBT434 For Parkinson's Disease

Sirtex Drops Varian $1.6b Offer For CDH China Grand $1.9b Bid

Federal Budget 2018 & Comment

China's CDH Bids $1.9b For Sirtex - Board Opposes

Merck Pays Viralytics $502m For Cavatak Cancer Immontherapy

WEHI $405m+ Canada Venetoclax For Cancer Deal



August BDI-40 Up 4%, ASX200 Up 1%
Big Caps Up 14%, NBI Up 5%

 Airxpanders Up 97%, Telix 38%; Neuren Down 50%, Admedus 19%

September 3, 2018

Winter smiled on Australian biotech, with the Biotech Daily Top 40 Index (BDI-40) up 9.2 percent for the three-month season, compared to the S&P ASX200 up 5.1 percent.
For the month of August, the BDI-40 climbed 3.6 percent while the ASX200 put on 0.6 percent.
But it was again the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) which streaked ahead, up a collective 13.8 percent, with CSL up 15.6 percent to break the $100 billion mark at $102,835 million, with Resmed up 9.8 percent to $22,087 million and Cochlear up 6.4 percent to $12,448 million.
Twenty-one of the BDI-40 companies were up, 17 fell and two were unchanged.
The steep rises by Pro Medicus putting on $185 million (and joining Nanosonics and Sirtex in the Billion Dollar Plus Club), Clinuvel up $115 million and Nanosonics up $108 million easily counterbalanced the deep falls by Neuren down $135 million and Mesoblast down $118 million, amid an array of modest rises.
The August BDI-40 best was Airxpanders, recovering 96.6 percent to $57 million, having fallen from $323 million at September 30, 2016 to a low of $24 million at May 31, 2018.
Telix had a more organic improvement up 38.1 percent to $174 million, followed by Genetic Signatures (26.8%), Avita (26.2%), Pro Medicus (21.3%), Clinuvel (19.5%), Impedimed (18.95%), Volpara (13.3%), Nanosonics (11.4%), Polynovo (10.7%) and Pharmaxis (10.6%).
Neuren led the falls, with some investors dismayed by a $600 million deal for Trofinetide in North America, down 49.8 percent to $136 million.
Admedus lost 19.1 percent to $38 million prior to a trading halt and a series of extended suspensions for a capital raising, followed by Compumedics (18.9%), Prescient (16.7%), LBT (15.4%), Reva (14.7%), Mesoblast (13.0%), ITL (11.8%), Benitec (11.1%), Orthocell (11.1%), Universal Biosensors (10.6%) and Optiscan (10.3%).
The August Nasdaq Biotechnology Index )NBI) climbed 4.8 percent, with Queensland’s Protagonist up 43.4 percent to $284 million, Redhill up 1.8 percent to $222 million and Vaxart (Biota) unchanged at $30 million.
Outside the BDI-40, Adalta, Cardiex, Bluechiip, IDT, Invitrocue, Medadvisor, Paradigm, Probiotec and Resapp continued to strengthen with most double their market capitalization 12 months ago, and some up four-fold.
The 16 companies in Cannabis Corner were a bit potty in August, with 12 experiencing small falls, two having small rises, but Elixinol Global and TPI returned to their previous highs.
BDI-40 v S&P ASX200 Jun 30, 2006 to Aug 31, 2018 
Big Caps (Cochlear, CSL, Resmed) Aug 31, 2015 To Aug 31, 2018


 Click here for Biotech Daily's archive



Biotech Daily Top 40 With Market Capitalization At Aug 31, 2018


* Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Innate, Mesoblast, Nanosonics, Neuren,
   Patrys, Polynovo, Prana, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: